Related Experiment Video
Updated: Jun 9, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
Emilio Portaccio1, Melinda Magyari2, Eva Kubala Havrdova3
1Department of NEUROFARBA, Unviersity of Florence, Florence, Italy.
Abstract:
Multiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central nervous system and a major cause of neurological disability in young adults. Its prevalence and incidence are increasing, and it has been estimated at over 2.8 million cases worldwide, in addition to recent trends towards a shift in MS prevalence to older ages, with peak prevalence estimates in the sixth decade of life. Although historically the relapsing and progressive phases of the disease have been considered separate clinical entities, recent evidence of progression independent of relapse activity (PIRA) has led to a reconsideration of multiple sclerosis as a continuum, in which relapsing and progressive features variably coexist from the earliest stages of the disease, challenging the traditional view of the disease course. In this Series article, we provide an overview of how the traditional description of the clinical course of MS and epidemiological trends in Europe have evolved. For this purpose, we focus on the concept of PIRA, discussing its potential as the main mechanism by which patients acquire disability, how its definition varies between studies, and ongoing research in this field. We emphasise the importance of incorporating the assessment of hidden clinical manifestations into patient management to help uncover and quantify the PIRA phenomenon and the possible implications for future changes in the clinical classification of the disease. At the same time, we provide insights into overcoming the challenges of identifying and defining PIRA and adopting a new understanding of the clinical course of MS.
Insights
Multiple sclerosis (MS) is increasingly affecting older adults, with progression independent of relapse activity (PIRA) now seen as a key driver of disability. Understanding PIRA is crucial for evolving MS clinical understanding and management.
Area of Science:
- Neuroscience
- Immunology
- Epidemiology
Background:
- Multiple sclerosis (MS) is a chronic, inflammatory, neurodegenerative disease impacting the central nervous system.
- MS is a leading cause of neurological disability in young adults, with increasing global prevalence and incidence.
- Recent trends show a shift in MS prevalence towards older age groups.
Purpose of the Study:
- To provide an overview of the evolving clinical course and epidemiological trends of MS in Europe.
- To focus on Progression Independent of Relapse Activity (PIRA) as a potential primary mechanism of disability acquisition.
- To discuss challenges in defining and identifying PIRA and its implications for MS classification.
Main Methods:
- Review of traditional clinical course descriptions and European epidemiological trends in MS.
- Analysis of the concept of Progression Independent of Relapse Activity (PIRA).
- Discussion of ongoing research, varying definitions of PIRA, and assessment of hidden clinical manifestations.
Main Results:
- Evidence suggests MS should be viewed as a continuum where relapsing and progressive features coexist early.
- Progression Independent of Relapse Activity (PIRA) is increasingly recognized as a significant factor in disability accumulation.
- The definition and identification of PIRA present ongoing challenges.
Conclusions:
- Reconsidering MS as a continuum challenges traditional views of its clinical course.
- Assessing hidden clinical manifestations is vital for quantifying PIRA and improving patient management.
- A new understanding of PIRA is essential for future clinical classification and treatment strategies in MS.
Related Concept Videos
Endocarditis II: Clinical features and Diagnostic Tests
Myocarditis II: Clinical features and Diagnostic Tests
Parkinson's Disease: Overview

